上海中药创新研究中心(以下简称“中心”)是在中国科技部和上海市人民政府的支持下，于 2000 年 4 月由上海市科委、上海市浦东新区政府和上海市张江高科技园区开发公司共同投资组建的中药现代化研究和开发机构，是国家中药现代化(上海)创新中心的依托单位，是国家生物医药基地重点建设的国家级专业孵化器之一，也是国家国际科技合作基地和上海市研究生联合培养基地。
Shanghai Innovative Research Center of Traditional Chinese Medicine (SIRC/TCM), as a research and development (R&D) institution for TCM modernization, was co-founded by Science and Technology Committee of Shanghai, Pudong New Area Government of Shanghai and Shanghai Zhangjiang Hi-Tech Park Development Corporation in April 2000. With supports from Ministry of Science and Technology of China and Shanghai Municipal Government, SIRC/TCM is designated as a core Innovation Center of TCM Modernization in Shanghai, a national key incubator for biomedical research in China, an international science and technology cooperation base in China, and a post-graduation co-education base in Shanghai.
As a national R&D center, SIRC/TCM is innovation-oriented and market-guided with the mission of developing novel drugs that are “from TCM, better than TCM”. Our approach of TCM modernization is based on two innovations generated by SIRC scientists: 1) a world-class comprehensive and interactive TCM database; 2) a novel concept of Post-Absorption and Metabolism Drugs (PAMD). The TCM database contains information about more than 30,000 compounds that are active ingredients of TCM herbs. The interactive structure of this database provides information of these compounds in a range of molecular structure, biological activity, herbs containing those compounds, toxicity, as well as TCM formula and their clinical application. The database has been widely used in screening for lead compounds, studying mechanisms of TCM drugs, predicting toxicity of herbal combinations, as well as creating new TCM formulas.
The concept of PAMD is to seek drug candidates among compounds existing in our body after orally taking TCM herbs, of which are with proven clinical benefits and demonstrated safety profiles. Given the fact that compounds absorbed by our body is less than 1% of those contained in TCM formula and many of them are metabolites of original active ingredients, PAMD strategy drastically improved efficiency in finding lead compounds from TCM for development of new single compound drugs as well as compound-combinations derived from TCM formulas. With the PAMD strategy, a series of proprietary drug candidates and products have been developed and some of them are near clinical stage or already on the market.
Research at SIRC/TCM employs a broad technological platform that integrates TCM informatics, phytochemistry, analytical technology, organic synthesis, molecular pharmacology, cell biology, toxicology, TCM genomics, transcriptomics, metabolomics, pharmacokinetics, computer-aid drug design and kilogram-scale chemical synthesis. We are well-connected with national and international scientists and pharmaceutical industries. People at SIRC/TCM believe that TCM is priceless treasure generated by Chinese people through clinical practice in past thousands of years and that innovative concepts with integrative technologies will eventually bring the ancient TCM to the modern medical sciences and revolutionize our approach in drug discovery as well as development of the modern pharmaceutical industry.